Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Factor VIII Deficiency Treatment Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Factor VIII Deficiency Treatment Market Status and Forecast (2016-2027)
      • 1.3.2 Global Factor VIII Deficiency Treatment Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Factor VIII Deficiency Treatment Supply by Company

    • 2.1 Global Factor VIII Deficiency Treatment Sales Value by Company
    • 2.2 Factor VIII Deficiency Treatment Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Factor VIII Deficiency Treatment Market Status by Category

    • 3.1 Factor VIII Deficiency Treatment Category Introduction
      • 3.1.1 Hemophilia A Drugs
      • 3.1.2 Hemophilia A Inhibitors Treatment
      • 3.1.3 Von Willebrand Disease Treatment
    • 3.2 Global Factor VIII Deficiency Treatment Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Factor VIII Deficiency Treatment Market Status by End User/Segment

    • 4.1 Factor VIII Deficiency Treatment Segment by End User/Segment
      • 4.1.1 Hospitals
      • 4.1.2 Clinics
      • 4.1.3 Other
    • 4.2 Global Factor VIII Deficiency Treatment Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Factor VIII Deficiency Treatment Market Status by Region

    • 5.1 Global Factor VIII Deficiency Treatment Market by Region
    • 5.2 North America Factor VIII Deficiency Treatment Market Status
    • 5.3 Europe Factor VIII Deficiency Treatment Market Status
    • 5.4 Asia Pacific Factor VIII Deficiency Treatment Market Status
    • 5.5 Central & South America Factor VIII Deficiency Treatment Market Status
    • 5.6 Middle East & Africa Factor VIII Deficiency Treatment Market Status

    6 North America Factor VIII Deficiency Treatment Market Status

    • 6.1 North America Factor VIII Deficiency Treatment Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Factor VIII Deficiency Treatment Market Status

    • 7.1 Europe Factor VIII Deficiency Treatment Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Factor VIII Deficiency Treatment Market Status

    • 8.1 Asia Pacific Factor VIII Deficiency Treatment Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Factor VIII Deficiency Treatment Market Status

    • 9.1 Central & South America Factor VIII Deficiency Treatment Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Factor VIII Deficiency Treatment Market Status

    • 10.1 Middle East & Africa Factor VIII Deficiency Treatment Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Factor VIII Deficiency Treatment Market Forecast by Category and by End User/Segment

    • 12.1 Global Factor VIII Deficiency Treatment Sales Value Forecast (2022-2027)
    • 12.2 Global Factor VIII Deficiency Treatment Forecast by Category
    • 12.3 Global Factor VIII Deficiency Treatment Forecast by End User/Segment

    13 Global Factor VIII Deficiency Treatment Market Forecast by Region/Country

    • 13.1 Global Factor VIII Deficiency Treatment Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Uniqure NV
      • 14.1.1 Company Information
      • 14.1.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.1.3 Uniqure NV Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Takeda
      • 14.2.1 Company Information
      • 14.2.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.2.3 Takeda Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Swedish Orphan Biovitrum
      • 14.3.1 Company Information
      • 14.3.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.3.3 Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Spark Therapeutics
      • 14.4.1 Company Information
      • 14.4.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.4.3 Spark Therapeutics Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Sangamo Therapeutics
      • 14.5.1 Company Information
      • 14.5.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.5.3 Sangamo Therapeutics Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Pfizer
      • 14.6.1 Company Information
      • 14.6.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.6.3 Pfizer Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Octapharma
      • 14.7.1 Company Information
      • 14.7.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.7.3 Octapharma Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Novo Nordisk
      • 14.8.1 Company Information
      • 14.8.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.8.3 Novo Nordisk Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Kedrion
      • 14.9.1 Company Information
      • 14.9.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.9.3 Kedrion Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Grifols
      • 14.10.1 Company Information
      • 14.10.2 Factor VIII Deficiency Treatment Product Introduction
      • 14.10.3 Grifols Factor VIII Deficiency Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 F. Hoffmann-La Roche
    • 14.12 Dimension Therapeutics
    • 14.13 CSL
    • 14.14 BioMarin Pharmaceutical
    • 14.15 Biogen Idec
    • 14.16 Bayer HealthCare
    • 14.17 Amarna Therapeutics

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Factor VIII Deficiency Treatment market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Factor VIII Deficiency Treatment market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Hemophilia A Drugs
      Hemophilia A Inhibitors Treatment
      Von Willebrand Disease Treatment

      Segmented by End User/Segment
      Hospitals
      Clinics
      Other

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Uniqure NV
      Takeda
      Swedish Orphan Biovitrum
      Spark Therapeutics
      Sangamo Therapeutics
      Pfizer
      Octapharma
      Novo Nordisk
      Kedrion
      Grifols
      F. Hoffmann-La Roche
      Dimension Therapeutics
      CSL
      BioMarin Pharmaceutical
      Biogen Idec
      Bayer HealthCare
      Amarna Therapeutics
      Buy now